Biotechnology
BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi

Key PointsBioMarin gains a second Fabry therapy that could reach patients beyond Galafold's…
View more
- BioMarin gains a second Fabry therapy that could reach patients beyond Galafold's amenable mutations.
- The subcutaneous candidate could become the first non-intravenous enzyme replacement option for Fabry disease.
- BioMarin's $70 million upfront bet deepens its Fabry franchise after the Amicus acquisition.
BioMarin Pharmaceutical Inc. (BMRN ) on October 29, 2026 announced an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease. Under the terms of the agreement, BioMarin will make an upfront payment of $70 million, and GC Biopharma and Hanmi are jointly eligible to receive up to an additional $405 million upon the completion of certain development and commercial milestones, plus tiered royalties on net sales of HM15421/GC1134A, according to the company’s announcement.
The license grants BioMarin worldwide rights to the candidate excluding Korea, where GC Biopharma and Hanmi retain commercialization rights for HM15421/GC1134A. Following the ongoing Phase 1/2 study, BioMarin will assume sole responsibility for all subsequent clinical development, manufacturing and commercialization of the therapy outside Korea.
HM15421/GC1134A is a human recombinant alpha-galactosidase A enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease. BioMarin stated that the candidate has the potential to be the first subcutaneous enzyme replacement therapy for Fabry disease and that it is designed to extend half-life and improve stability relative to currently available enzyme replacement therapies, supporting subcutaneous dosing. The company said that in preclinical studies HM15421/GC1134A demonstrated differentiated efficacy across key measures including renal function, vascular health and peripheral nervous system outcomes. The candidate received Orphan Drug Designation from the U.S. Food and Drug Administration in 2024.
“This agreement reflects our growing commitment to the Fabry community, building on the acquisition of Amicus earlier this year,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. “As we continue to add to our clinical portfolio, both through internal research and external programs, HM15421/GC1134A is an excellent fit and could allow us to reach a new generation of patients with Fabry beyond those with mutations amenable to treatment with GALAFOLD.”
Ongoing Phase 1/2 Study
HM15421/GC1134A is being evaluated in an open-label, dose-ranging, proof-of-concept first-in-human Phase 1/2 trial registered as NCT06858397 on ClinicalTrials.gov, with GC Biopharma as lead sponsor and Hanmi Pharmaceutical as collaborator. The registry lists the study as recruiting, with an actual start date of May 14, 2025, an estimated enrollment of 18 participants and an estimated completion date of August 30, 2028.
Participants are assigned sequentially to three dose cohorts (low, mid and high) and receive the drug subcutaneously. The primary outcome measure is the incidence and characteristics of adverse events over a period of up to 48 weeks. Secondary measures include pharmacokinetic parameters such as maximum serum concentration and terminal elimination half-life, and pharmacodynamic measures including plasma and urine Gb3 and lyso-Gb3 levels and change in estimated glomerular filtration rate. Recruiting sites listed in the registry are located in the U.S. states of California, Kansas, Minnesota, Ohio, Pennsylvania and Virginia, as well as in Argentina and South Korea.
Development History
GC Biopharma announced on September 3, 2024 that the FDA had cleared the investigational new drug application for the Phase 1/2 trial of the therapy, which the two Korean companies are co-developing under the name LA-GLA. Hanmi’s announcement was posted on September 2, 2024. GC Biopharma dated the FDA’s Orphan Drug Designation of LA-GLA to May 2024 and said the trial was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LA-GLA in patients with Fabry disease.
Hanmi characterized LA-GLA as “the world’s first once-monthly subcutaneous treatment” for Fabry disease. According to the companies’ 2024 announcements, current treatment for Fabry disease includes enzyme replacement therapy involving intravenous administration of a recombinant enzyme. Hanmi stated that this approach requires patients to visit the hospital every two weeks for an infusion and described limitations of the current method including the burden of prolonged intravenous therapy and insufficient efficacy in preventing the progression of kidney disease. GC Biopharma said preclinical studies conducted to date demonstrated the therapy’s pharmacological activity, including kidney function improvements and effects on other disease manifestations.
BioMarin described the license as adding a second potential treatment for Fabry disease. The agreement follows BioMarin’s completion of its acquisition of Amicus Therapeutics on April 27, 2026, at $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. That acquisition added Galafold (migalastat), which BioMarin described as the first oral treatment for Fabry disease, indicated for adults with amenable GLA variants. Amicus estimated that approximately 35 to 50 percent of people living with Fabry disease may have amenable GLA variants, with amenability rates varying by geography, and Galafold is approved in more than 40 countries including the United States, the European Union, the United Kingdom and Japan. The transaction also added Pombiliti + Opfolda, a two-component therapy for Pompe disease, and U.S. rights to DMX-200, an investigational small molecule in Phase 3 development for focal segmental glomerulosclerosis.
Fabry disease is a rare, X-linked lysosomal storage disorder caused by inherited genetic changes in the GLA gene, which hamper activity of the enzyme alpha-galactosidase A. Reduced enzyme activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the symptoms of Fabry disease, including pain, kidney failure and increased risk of heart attack and stroke. The symptoms can be severe, differ from person to person and begin at an early age, according to the BioMarin release.
BioMarin, founded in 1997 and based in San Rafael, California, describes itself as a global rare disease biotechnology company with nine commercial therapies. GC Biopharma, formerly known as Green Cross Corporation, is headquartered in Yongin, South Korea, and is a plasma protein and vaccine manufacturer.












